ClinicalTrials.gg
CompletedNCT00891332Updated Jan 18, 2012

Study of S-1 Plus LV for Untreated Metastatic Colorectal Cancer

A Phase 2 interventional study of S-1 plus LV (The combination therapy of S-1 and Leucovorin) in Colorectal Cancer, sponsored by Taiho Pharmaceutical Co., Ltd.. Completed at 6 sites in 2 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-01-18.

Sponsored by Taiho Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
73
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing tegafur in Colorectal Neoplasms — 2 open to participants now, 2 under way, none of them phase 3. Tegafur · Colorectal Neoplasms.

Enrollment
7th of 18
73 · median 55
Started
2008
with 1 other
Phase 2
12 of 18
2 open now
Registered
9th of 18
by date
Lead sponsor
4 of 18
Taiho Pharmaceutical Co., Ltd.

Among the 18 studies testing tegafur in Colorectal Neoplasms, this one is the 7th largest by enrollment, is one of 2 that started in 2008, is one of 12 in phase 2, and was the 9th registered.

Colorectal Neoplasms

6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

2 of the 18 studies testing tegafur in Colorectal Neoplasms are open now. Recruiting first, the newest first:

All 2 open studies →

Where they have run

About tegafur

Tegafur: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing tegafur in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This is a multicenter study designed to evaluate the response rate of S-1 plus Leucovorin (1 week on and 1 week off) as first -line treatment for patients with metastatic colorectal cancer.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologically proved adenocarcinoma
  • Unresectable and recurrent colorectal cancer
  • Age20 ≤ at enrollment
  • Performance status 0 or 1 ()
  • No prior treatment (ex. radiation therapy, chemotherapy, hormonal therapy) to advanced disease. Patients who received chemotherapy more than 180 days before enrollment can be allowed but those who received S-1 containing treatment shall be excluded
  • Adequate hematologic, hepatic and renal functions
  • At least one by criteria

Exclusion criteria

Exclusion Criteria:

  • Serious drug
  • Pregnant or nursing
  • Bleeding from gastrointestinal tract
  • Diarrhea
  • Simultaneously active double cancer
  • Serious illness or medical condition
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    1

    S-1 plus LV

    Drug: S-1 plus LV (The combination therapy of S-1 and Leucovorin)

Interventions

  • DrugS-1 plus LV (The combination therapy of S-1 and Leucovorin)

    Drug pages: Tegafur · Gimeracil · Oxonic Acid

    S-1 40-60 mg bid day 1~day 7 LV 25 mg bid day 1~day 7

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    Time frame: During chemotherapy

Secondary outcomes

  1. Safety

    Time frame: During chemotherapy

  2. Progression free survival (PFS)

    Time frame: Until progression

  3. Disease control rate(DCR)

    Time frame: During chemotherapy

  4. Time to treatment failure (TTF)

    Time frame: Until progression

  5. Overall survival (OS)

    Time frame: Over two years from registration

  6. Feasibility

    Time frame: During chemotherapy

  7. Pharmacokinetics

    Time frame: During chemotherapy

07

Study locations

6 sites
  • Sun Yat-sen University Cancer Center, Division of Oncology
    Dong feng Dong road,Guangzhou, Guangdong 510060, China
  • Shanghai Fudan University Cancer Hospital, Division of Oncology
    Dong An Road, Shanghai, 200032, China
  • PLA 307 Hospital, No.4 Division of Oncology
    East Avenue, Fengtai District, Beijing, 100071, China
  • Beijing Cancer Hospital, Digestive System Medicine Department
    Fucheng Road, Haidian District, Beijing, 100036, China
  • Cancer Institute & Hospital Chinese Academy of Medical Sciences, Division of Oncology
    Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China
  • Graduate School of Medical Sciences Kumamoto University
    1-1-1, Honjo Kumamoto-city, Kumamoto, 860-8556, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Jul 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2009
First posted
May 1, 2009
Start
Oct 2008
Primary completionActual
Jul 2011
CompletionActual
Nov 2011
Last update
Jan 18, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00891332
Responsible party
Sponsor
First posted
May 1, 2009
Start date
Oct 2008
Primary completion
Jul 2011
Completion
Nov 2011
Last update
Jan 18, 2012

Study contacts

Hideo Baba, M.D.
principal investigator · Graduate School of Medical Sciences Kumamoto University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tegafur · Gimeracil · Oxonic Acid

Start the discussion